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ethical debate (1, 6-15). Opponents say that Northfield
Laboratories has inappropriately influenced regulatory
decisions and abused the bureaucratic system in order to
gain approval for a questionable experimental protocol
(7, 10, 13). Conversely, proponents argue that
prolonged suspension of informed consent is a necessity
for effective characterization of safety and efficacy of
prospective emergency therapies (6, 12, 14). This
putative necessity is hinged upon the fact that the
majority of patients targeted by new emergency
therapies are incapacitated at the time of enrollment (2-
4, 16). What is not debated is that the completion of the
pivotal phase III clinical trial for Polyheme is
surrounded by a cloud of ethical tension…
THE ORIGIN OF BLOOD TRANSFUSIONS &
ARTIFICIAL BLOOD
In 1909, the successful characterization of the “ABO”
and “Rhesus” blood type antigens on the surface of the
red blood cell (RBC) allowed clinicians to begin
transfusing trauma patients with whole allogeneic blood
(17, 18). Since then, allogeneic blood transfusions have
become ubiquitous in clinical medicine (19, 20).
Interestingly, even though blood transfusions are the
gold standard of care, the efficacy and safety of
allogeneic red cell therapy has never been rigorously
tested via the clinical trial process (20-22). Indeed, the
indications for treatment are largely based on common
medical practice, tradition, and expert advice (20-22).
Thus, comparing the safety and efficacy of a blood
substitute to the standard of care may prove to be
difficult.
The most serious motivation for the development of a
blood substitute is the worldwide shortage of safe and
viable allogeneic donor blood (7). A recent report on
blood donations found that during 2001, 12.7% of
hospitals reported a cancellation of surgeries due to
donor blood shortage and 18.9% reported a shortage of
blood for non-surgical purposes (19). In addition, the
stress on the donated blood supply is projected to
increase in the coming years (23).
In spite of many research initiatives, blood substitute
investigations are not yet focused on providing a long
PROLOGUE: A HYPOTHETICAL CASE
A 35 year old female, victim of a motor vehicle
accident, sustained life threatening injuries leading to
hemorrhagic shock. When paramedics arrived at the
scene the patient was unconscious. Due to acute blood
loss, the patient’s blood pressure and oxygen saturation
were critically low, leaving only a short therapeutic
window to save the patient. The paramedics were
unsure whether the current standard of care, an infusion
of saline, would be adequate to sustain the patient’s life
until the nearest hospital could be reached. These
paramedics, however, have been instructed to enroll
hemorrhagic shock victims in a phase III clinical trial to
test the efficacy and safety of an artificial oxygen
carrying fluid or “blood substitute”. Like saline, the
blood substitute would increase the patient’s blood
pressure. In addition, it could also help supply tissues
with much needed oxygen, potentially reducing the
chance of mortality.
Because the patient is unconscious, however, the
paramedics are placed at the center of an ethical
dilemma. If the injuries are sufficiently severe, infusion
of the experimental fluid may maintain the patient’s
vitals long enough to be safely transported to a trauma
center. The patient, however, is incapacitated, so there is
no feasible way to obtain proper informed consent.
Polyheme®, a blood substitute, has completed a
pivotal phase III clinical trial in which the ethical
dilemma exemplified in this hypothetical situation was
commonplace (1). Because this clinical trial examines a
new emergency therapy, the Food and Drug
Administration (FDA) invoked Title 21, Section 50.24,
Subpart B of the Code of Federal Regulations in order
to grant the creators of Polyheme, Northfield
laboratories Inc. (Illinois, USA), an exemption from
acquiring informed consent (2-5).
The waiver of informed consent has caused the
clinical trial itself to become the center of an intense
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oxygen as plasma (38, 39, 45). HBOCs, like Polyheme,
are solutions of modified hemoglobin in plasma-like
fluids. In addition to a reduced side-effect profile,
HBOCs deliver oxygen to tissues through facilitated
diffusion (via hemoglobin) instead of passive diffusion
(27, 46). Thus, HBOCs have proven more efficacious
than PFCs in clinical settings (34, 47).
Because extracellular hemoglobin degrades into
nephrotoxic dimers, initial attempts to use free-floating
or “stroma-free” hemoglobin (SFHb) have failed (46).
In addition, because hemoglobin extravasates into
endothelial cells and binds the vasodilator nitric oxide,
it is a vasoconstrictor (48). To alleviate these problems,
various methods to modify hemoglobin including cross-
linking, conjugation, and polymerization have been
investigated(33).
The earliest endeavours to prevent the dimerization of
SFHb used cross-linking agents like diaspirin or
glutaraldehyde to covalently bind hemoglobin’s
subunits together (49, 50). While nephrotoxicity was
reduced somewhat, because cross-linked SFHb is still
small enough to extravasate into endothelial cells, its
vasoactive properties were still significant (48, 50).
Furthermore, cross-linked hemoglobin caused cardiac
toxicity (27).
In addition to reducing nephrotoxicity, increasing the
molecular weight of SFHb by conjugation with
polyethylene glycol or malemide has been shown to
lengthen intra-vascular half-life, thereby reducing
vasoactivity (51). One pre-market conjugated SFHb
solution, Hemospan, has shown moderate efficacy and
an acceptable safety profile after phase II clinical trials
(47). The manufacturers, Sangart Inc. (California,
USA), will soon begin phase III clinical trials (27).
The last common modification of SFHb polymerizes
tetramers into macromolecular chains (28).This process
affords the same benefits as cross-linking and
conjugation (31, 34, 50). By controlling the size of the
polymers, oxygen disassociation characteristics and
nitric oxide binding properties can also be fine tuned
(29, 31, 50). Similarly to Northfield Laboratories’
Polyheme, Biopure Inc. (Massachusetts, USA) has
manufactured a polymerized bovine hemoglobin
formulation called Hemopure (29). Bovine SFHb comes
from a plentiful and renewable resource and has the
advantage of not requiring 2,3-diphosphoglycerate to
facilitate proper oxygen offloading (27, 33). Hemopure
is currently licensed in South Africa and pivotal phase
III trials have been completed in North America for use
in orthopaedic surgery (46).
Northfield Laboratories’ Polyheme is an HBOC
synthesized by polymerization of hemoglobin extracted
from expired human donor blood (34). Due to
term alternative for allogeneic whole blood. The acute
conditions currently targeted by blood substitutes
include hemorrhagic shock or ischemic stroke (24, 25).
Because these pathophysiologies are encountered
primarily in emergency situations (26, 27), clinical
applications of blood substitutes aim only to prolong
patient survival until allogeneic blood transfusions
become available (27-30).
Outside of the hospital, long-term storage of
allogeneic blood is impractical and donor blood type
cannot be cross-matched to the recipient (7). Thus,
paramedics are restricted to saline, a volume expander,
as the standard treatment for hemorrhagic shock (11,
12). Like saline, blood substitutes replenish lost blood
volume, do not carry blood type antigens, and are stable
for long periods of time at room temperature (31-33). In
addition, blood substitutes can facilitate oxygen
delivery to ischemic tissues, highlighting an important
advantage over the use of saline(34).
In the hospital, in spite of enhanced screening
methods for blood-borne illnesses, it is still impossible
to be certain that allogeneic transfusions are free of
pathogens (6, 30, 35). For example, during the
remission periods of retroviral life cycles, viral particles
cannot be detected (36). Many serious infections
including HIV, hepatitis B & C, malaria, vCJD and
cytomegalovirus are still transmitted by transfusions
(20, 36). Blood substitutes avoid this risk by undergoing
pasteurization, ultrafiltration or other sterilization
techniques (32, 36-39).
Lastly, a potential market niche for blood substitutes
is the population of patients that refuse allogeneic blood
transfusion due to religious beliefs (34, 40). For a blood
substitute to be suitable for those with special religious
needs, no part can be derived from an animal or human
source (21, 28). Compassionate use of Polyheme has
already been clinically implemented in cases where
allogeneic blood transfusions are refused (41).
The potential for blood substitutes to address the
problems with current therapies has been recognized.
To date, investigation of blood substitutes has fostered
over eighteen clinical trials resulting in granted
licensures in multiple foreign countries (26, 27, 33, 37,
42, 43).
AN OVERVIEW OF HEMOGLOBIN-BASED
OXYGEN CARRIERS
The founder of the field of blood substitutes is Dr.
Thomas Chang of McGill University, who in the late
1950s, encapsulated hemoglobin molecules in a
polyvinyl chloride (PVC) membrane (44). Since then,
two major categories of blood substitutes have arisen:
perfluorocarbons (PFCs) and hemoglobin-based oxygen
carriers (HBOCs). PFCs are chemically inert organic
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55).
The FDA and DHHS regulations attempt to find a
balance between expediting approval for emergency
therapies and ethical practices of clinical investigation.
In some cases, however, the interpretation of these
regulations can lead to questionable practices.
Having commenced phase I clinical trials in 1991,
Polyheme’s journey through pivotal phase III studies
just recently finished in May 2007 (56, 57). Early trials
to determine the efficacy and safety of large volume
Polyheme infusions (up to 20 units) were completed in
2002 (56, 58). These secondary studies showed
Polyheme’s capability to sustain patient survivability in
conditions of extreme endogenous hemoglobin
deprivation, where death is statistically certain (31, 34).
After reviewing the results, the FDA granted Polyheme
permission to sponsor a pivotal phase III clinical trial
involving 720 hemorrhagic shock victims, pursuant
under the ERW (11, 13, 57).
The phase III clinical trial was conducted in
conjunction with 32 trauma centers across 19 US states
and continued from July 2006 to May 2007 (5, 57). The
trial has two distinct phases, a “pre-hospital” phase, and
an “in-hospital” phase. In the pre-hospital phase,
incapacitated trauma patients are randomized between
Polyheme and the current standard of care, saline. Upon
arrival at the hospital, patients previously given saline
in the pre-hospital phase are given allogeneic blood,
while patients previously given Polyheme in the pre-
hospital phase are continued on the Polyheme treatment
for up to 12 hours. The in-hospital phase of this study
uses Polyheme in spite of the availability of allogeneic
whole blood (5). Furthermore, if the patient was
enrolled in the trial while unable to give informed
consent, infusion of Polyheme at the hospital site can be
performed without proper notification either the
subjects themselves or a legally authorized
representative (3, 10, 11).
The pre-hospital phase of this trial is not heavily
debated and the necessity of the ERW rule is widely
accepted (6-14). The in-hospital phase of this study,
however, is heavily debated. The major point of
contention comes from the fact that patients who were
randomized to the Polyheme group in the pre-hospital
phase were not treated with allogeneic whole blood
transfusions upon arrival at the hospital (6-14). Previous
studies performed under the ERW, most notably the
public access defibrillator trial, did not have a protocol
with a questionable in-hospital phase (54, 59, 60). Thus,
the ethics pertaining to informed consent in the
Polyheme clinical trial present a novel situation.
Opponents of the in-hospital phase do not discount the
scientific validity of a clinical comparison between
purification and polymerization, an appreciable
vasoconstrictory effect is not associated with Polyheme
and no adverse cardiovascular events were reported in
preliminary safety studies (31, 34). Recently, Polyheme
has completed a controversial pivotal phase III clinical
trial and may be the first HBOC to enter Phase IV
marketing trials (27, 33, 37).
THE POLYHEME CLINICAL TRIALS: ETHICS
AND EDITORIAL
In 1996, the Department for Health and Human
Services (DHHS) and the FDA enacted complementary
regulations for waiving the requirement for informed
consent in certain emergency research protocols (2-4).
21CFR50.24 and 45CFR46 are federal regulations
called the ‘Emergency Research Waiver’ (ERW) rules
that allow an incapacitated person to be enrolled in a
clinical trial without consent of a legally authorized
representative, provided that the following criteria are
fulfilled (2-4, 10):
1. The subject must be suffering from a life-
threatening condition necessitating immediate
treatment.
2. Obtaining informed consent from a legally
authorized representative must be infeasible given
the time frame in which the subject must be
treated.
3. Previous clinical evidence must indicate that the
investigated therapy will grant a serious benefit to
the subject.
4. The investigators must make an effort to contact a
legally authorized representative during the given
therapeutic window.
5. An independent committee must review collected
data of the ongoing study.
6. Available treatments must be “unproven and
unsatisfactory” (2).
7. Principal investigators must meet with the
communities from which the subjects will be
drawn, and publicly disclose pertinent aspects of
the study including the risks and benefits.
Potentially life-saving therapies for which there are
no other methods of treatment can also be given special
consideration under federal law. A “Special Protocol
Assessment” (SPA) is a stipulation outlined in the 1997
US Modernization Act (52, 53) that allows a clinical
trial to be streamlined for fast approval; trials which led
to the installation of publicly available defibrillators, for
instance, were conducted under this stipulation (54) . To
be eligible, the experimental therapy must have no
existing alternative. The FDA has deemed that
Polyheme meets these requirements and has granted
Vol. 11 No. 1 61 Blood Substitutes-The Polyheme Trialsconcerns. Before one IRB evaluation, the principal
investigator of the Polyheme trial was privy to
information that one member of the IRB had
reservations about the in-hospital phase of the trial.
Before the IRB convened to deliberate about the study,
the application for approval of the trial at that site was
withdrawn by Northfield Laboratories (10). In another
case, one IRB returned the application for approval to
Northfield Laboratories citing concerns pertaining to
the in-hospital phase of the study. In order to allow
Northfield Laboratories a chance to address these
concerns, the IRB requested that they amend and
resubmit their request for ERW approval. Northfield
Laboratories simply elected not to respond and to
pursue study opportunities in other cities. Because the
IRB never formally denied the study, a report was never
authored, and the FDA and other IRBs were not
informed (10, 11).
In the first case, a lack of confidentiality pertaining to
IRB proceedings allowed Northfield Laboratories to
avoid regulatory mechanisms in order to prevent an
unfavourable outcome. In the second instance, an
unwarranted decision by an IRB allowed Northfield
Laboratories to sidestep regulatory mechanisms. In
order to deter clinical trial sponsors from attempting to
bypass regulatory procedures, two rules should be
enacted:
1. Once a protocol has been submitted for
assessment, the sponsor may not retract the
submission.
2. Irrespective of whether a sponsor intends to
continue pursuing a clinical trial for a submitted
protocol, the IRB should evaluate it and officially
inform relevant organizations of their findings.
Implementing these two regulations creates an
incentive for sponsors to be absolutely certain the
submitted protocol is of the highest integrity.
Another notable obstacle to effective review of the
Polyheme protocol is the lack of malleability in the
regulatory elements of the SPA. The SPA specifies that
once the FDA and sponsor confirm an SPA agreement,
the study protocol is locked until completion of the
study. Furthermore, SPA status can only be granted
before the study is evaluated. There are only four
allowable exceptions to these rules (52, 53):
1. Amutual written agreement is formulated between
sponsor and FDA outlining changes to be made.
2. A “substantial scientific issue essential to
determining the safety or effectiveness of the
drug” is characterized as unacceptable.
3. The sponsor does not adhere to the agreed upon
Polyheme and allogeneic whole blood, but they charge
that such a comparison must be conducted with the full
cooperation and informed consent of patients or power
of attorney (10, 13). A further point of contention exists
due to dysfunction in the regulatory mechanisms for
clinical trials falling under the ERW and the SPA. In
particular, in 2006 Kipnis et al. uncovered a number of
hindrances to the effectiveness of institutional review
board (IRB) and FDA consideration of the Polyheme
trial (10).
First, Northfield Laboratories was allowed to maintain
secrecy of the specifics of the experimental protocol
and research methodologies relevant to the study. Only
after signing non-disclosure forms were IRBs and the
FDA allowed to review the study protocol (10). In
addition, although Northfield Laboratories did discuss
aspects of the study including the risks and benefits, the
study protocol itself was not disclosed at community
meetings; there is no requirement to do so under the
ERW (2, 4, 61). It is reasonable that a company should
be permitted to protect its intellectual property; the non-
disclosure, however, of the Polyheme research protocol
seems to be in direct contradiction with stipulations six
and seven as previously outlined in the criteria to be
granted an ERW (2,4). In the case of an ERW,
community consultations are essentially a surrogate
method to facilitate informed consent (3, 10, 15). For all
intents and purposes, ERWclinical trials enroll an entire
community as test subjects. Accordingly, the
requirements for surrogate informed consent should be
more stringent than for studies where only one subject
is being implicated. For example, in a more recent ERW
clinical trial that tests the “ResQPump”, an automated
CPR device, the investigators went to great lengths to
fulfill the requirement for community consultations.
Specifically, 136 community organizations were
contacted, major television and radio networks were
sent press releases, 2 local newspapers were informed
and multiple public service announcements were aired
on television and radio. Because of this effort,
attendance at community consultation meetings was
tripled over previous ERW Clinical trials (59).
Asecond obstacle arises because the process by which
an IRB reviews a clinical trial protocol is hindered by
ineffective regulatory mechanisms and the interplay
between ERA and SPA conditions (3, 10, 11).
Normally, when an IRB decides to disapprove of a
multi-center study protocol, it is required to report their
rejection to the sponsor of the study, the local
investigator, the FDA, and all other IRBs reviewing the
same study or studies with similar protocols (2, 4).
In this case, however, the research of Kipnis et al.
revealed two mechanisms utilized by Northfield
Laboratories to prevent IRBs from reporting their
2008 McGill Journal of Medicine 62victims upon arrival at the hospital is unethical. Thus,
the regulations concerning the informed consent of
incapacitated patients for clinically investigating
emergency therapies should be reviewed.
In spite of the concerns surrounding the design of the
Phase III clinical trials, Polyheme needed to be given
the opportunity to prove its efficacy in a clinical setting.
If Polyheme fulfills the promises its creators have made,
clinical outcomes for pre-hospital hemorrhagic shock
victims will be drastically improved.
APPENDIX – ABBREVIATIONS
RBC – Red Blood Cell
HBOC – Hemoglobin Based Oxygen Carrier
SFHb – Stroma-Free Hemoglobin
PFC – Perfluorochemical
HIV – Human Immunodeficiency Virus
vCJD – Variant Creutzfeldt-Jakob Disease
IRB – Institutional Review Board
FDA – Food and Drug Administration
DHHS – Department of Health and Human Services
ERW – Emergency Research Waiver
SPA – Special Protocol Assessment
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